Analysis and Recommendations. Without an integrated national medicines policy, the Bulgarian pharmaceutical sector is characterized by various highly prescriptive and at times, arguably counterproductive policy levers. While the regulatory framework has been largely brought into line with current EU standards, existing mechanisms for listing, pricing and subsidizing medicines are not ensuring adequate value for money for the NHIF, and are contributing to inefficiencies in the public financing of the health sector. Current pharmaceutical policy settings appear focused on limiting NHIF outlays rather than rather than prioritizing access and affordability, and afford little financial protection to patients.
Appears in 3 contracts
Sources: Advisory Services Agreement, Advisory Services Agreement, Advisory Services Agreement